This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Ankle Osteoarthritis

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: August 17, 2005
Last updated: March 17, 2015
Last verified: March 2015
This clinical study is to evaluate the safety and efficacy of Synvisc in patients with symptomatic ankle osteoarthritis (OA). Patients will be given Synvisc, with the possible administration of a second injection where insufficient symptomatic pain relief was experienced during the initial 3 months follow up period.

Condition Intervention Phase
Osteoarthritis Device: Synvisc (hylan G-F 20) Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Pain relief

Study Start Date: November 2003
Estimated Study Completion Date: February 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with symptomatic OA pain of ankle (talo-crural)

Exclusion Criteria:

  • Patients with current or prior conditions or treatments that would impede measurements of efficacy or safety
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00131768

Sportmedizinisches Institut Frankfurt am Main e.V. Orthopadie
Frankfurt, Germany, D-60528
Johanna Etienne Krankenhaus
Neuss, Germany, D-41462
Instituti Ortopedici Rizzoli
Bologna, Italy, 40136
Ospedale Santa Chiara, Clinica Ortopedica, Universita di Pisa
Pisa, Italy, 56126
Academisch Medisch Centrum
Amsterdam, Netherlands, 1100 DD
Sponsors and Collaborators
Genzyme, a Sanofi Company
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

Responsible Party: Medical Monitor, Genzyme Corporation Identifier: NCT00131768     History of Changes
Other Study ID Numbers: SYNV-003-02
Study First Received: August 17, 2005
Last Updated: March 17, 2015

Keywords provided by Sanofi:
osteoarthritis of the ankle

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Protective Agents
Physiological Effects of Drugs processed this record on August 18, 2017